Country: Malta
Language: English
Source: Malta Medicines Authority
FOLIC ACID
Adelco-Chromatourgia Anthinon E. Colocotronis Bros S.A. 37 Pireos Str, 183 46, Moschato, Athens, Greece
B03BB01
FOLIC ACID 5 mg
TABLET
FOLIC ACID 5 mg
POM
ANTIANEMIC PREPARATIONS
Authorised
2005-12-26
FILICINE Folic Acid NAME: FILICINE QUALITATIVE AND QUANTITATIVE COMPOSITION: _ACTIVE INGREDIENT:_ FILICINE 5mg FOLIC ACID / tablet, yellow flat tablets 8mm in diameter _EXCIPIENTS_: Lactose Monohydrate, Starch maize, Magnesium stearate. PHARMACEUTICAL FORM: Yellow Tablets. DRUG CLASSIFICATION: Vitamin PACKAGE: Box x 30 (blister 3 X 10 tabs) Box x 1000 (blister 100 X 10 tabs) MARKETING AUTHORIZATION HOLDER AND MANUFACTURER: ADELCO CHROMATOURGIA ATHINON E. COLOCOTRONIS BROS. S.A. 37, PIREOS STR., 183 46 MOSCHATO-ATHENS, TEL: 210 4819311-4 FAX: 210 4816 790 WHAT YOU SHOULD KNOW ABOUT THE DRUG YOU WERE PRESCRIBED GENERAL INFORMATION: Filicine is a vitamin medicinal product which participates in hematopoiesis and is essential for the production of blood cells. The deficiency of folic acid causes anemias of megaloblastic form. INDICATIONS: Folic acid (pteroglutamic acid) is indicated for the treatment of megaloblastic anemia caused by the deficiency of folic acid. Pathophysiological conditions that are likely to lead to a deficiency of folic acid and to megaloblastic anemia are the following: 1. Inadequate diet (vegetarian eating, alcoholism, elimination of the vitamin during food cooking, undernourishment) 2. Absorption disorders at the gastrointestinal tract (chronic diarrheas, celiac disease, infiltrative and granulomatous diseases, such as in lymphoma and Whipple's disease) 3. Increased needs of the body in folic acid (pregnancy, childhood, hemolytic anemias, hyperthyroidism, infections, liver cirrhosis, extensive skin lesions) 4. Deficiency due to medication treatment ( Read the complete document
Page 1 of 5 1. TRADE NAME OF THE PHARMACEUTICAL PRODUCT FILICINE TABLET 2. QUALITATIVE AND QUANTITATIVE COMPOSITION DRUG SUBSTANCE: FOLIC ACID 5 mg / tablet 3. PHARMACEUTICAL FORM Tablets 4. CLINICAL CHARACTERISTICS 4.1. THERAPEUTIC INDICATIONS Folic acid (pteroglutamic acid) is indicated for the treatment of megaloblastic anemia which is caused by folic acid deficiency. Pathophysiological conditions that may cause a lack of folic acid and megaloblastic anemia are the following: 1. Dietary deficiencies (vegetarian diet, alcoholism, destruction of the vitamin during cooking, malnutrition) 2. Disturbances related to its absorption by the gastrointestinal tract (chronic diarrheas, celiac sprue, invasive and granulomatous diseases, such as lymphoma and Whipple’s disease) 3. Increased needs of the body in folic acid (pregnancy, childhood, hemolytic anemias, hyperthyroidism, infections, hepatic cirrhosis, extensive cutaneous lesions) 4. Lack because of pharmaceutical therapy (anti-epileptics- phenytoin, barbiturates, primidone-contraceptives, alcohol, antagonists of folic acid- methotrexate, aminopterine, trimethoprime-cycloserine) 5. Enzymatic disorders (Dihydrofolic acid reductase and Glutamate forminotransferase). It is also indicated for chronic hemolytic anemias, chronic hemodialysis, usually in combination with iron. 4.2. POSOLOGY AND MODE OF ADMINISTRATION : _INITIAL THERAPEUTIC DOSE _ ADULTS : The therapeutic dosage for folic acid is the following: Megaloblastic anemia, adults, children, elderly, usual dose 1 to 5 mg per day orally for 7 to 14 days. In most patients, 5-1 Read the complete document